SG11202105272YA - Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same - Google Patents
Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using sameInfo
- Publication number
- SG11202105272YA SG11202105272YA SG11202105272YA SG11202105272YA SG11202105272YA SG 11202105272Y A SG11202105272Y A SG 11202105272YA SG 11202105272Y A SG11202105272Y A SG 11202105272YA SG 11202105272Y A SG11202105272Y A SG 11202105272YA SG 11202105272Y A SG11202105272Y A SG 11202105272YA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroarylmethylureas
- arylmethylureas
- analogues
- substituted
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
- A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
- A01N47/30—Derivatives containing the group >N—CO—N aryl or >N—CS—N—aryl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862778471P | 2018-12-12 | 2018-12-12 | |
US201962896237P | 2019-09-05 | 2019-09-05 | |
PCT/US2019/065756 WO2020123674A1 (en) | 2018-12-12 | 2019-12-11 | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105272YA true SG11202105272YA (en) | 2021-06-29 |
Family
ID=71076715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105272YA SG11202105272YA (en) | 2018-12-12 | 2019-12-11 | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230045421A1 (en) |
EP (1) | EP3893645B1 (en) |
JP (2) | JP7410950B2 (en) |
KR (1) | KR20210102942A (en) |
CN (1) | CN113923988A (en) |
AU (2) | AU2019397481B2 (en) |
BR (1) | BR112021011381A2 (en) |
CA (1) | CA3122568A1 (en) |
IL (2) | IL310611A (en) |
MX (1) | MX2021006997A (en) |
PH (1) | PH12021551369A1 (en) |
SG (1) | SG11202105272YA (en) |
TW (1) | TWI827760B (en) |
WO (1) | WO2020123674A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202214585A (en) * | 2020-06-08 | 2022-04-16 | 加拿大商愛彼特生物製藥公司 | Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same |
TW202214572A (en) * | 2020-06-17 | 2022-04-16 | 加拿大商愛彼特生物製藥公司 | Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same |
JP6971444B1 (en) * | 2021-02-26 | 2021-11-24 | 千住金属工業株式会社 | flux |
KR20230051940A (en) * | 2021-10-12 | 2023-04-19 | (주)에이엠사이언스 | Novel capsid assembly inhibitors |
KR20230051939A (en) * | 2021-10-12 | 2023-04-19 | (주)에이엠사이언스 | Novel capsid assembly inhibitors |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4623662A (en) * | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
WO1991013871A1 (en) * | 1990-03-12 | 1991-09-19 | Yamanouchi Pharmaceutical Co., Ltd. | Monourea derivative and its salt |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
ATE173159T1 (en) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | ORAL MEDICINAL DOSAGE FORMS BASED ON HYDROXYETHYL CELLULOSE WITH DELAYED RELEASE |
EP0634402A1 (en) * | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
US6211373B1 (en) * | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
WO1998033501A1 (en) | 1997-01-31 | 1998-08-06 | Avid Therapeutics Inc. | 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same |
WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
EP1242057A2 (en) | 1999-11-02 | 2002-09-25 | DepoMed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
PT1251832E (en) | 2000-02-04 | 2007-01-31 | Depomed Inc | Shell-and-core dosage form approaching zero-order drug release |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
WO2002096404A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
CL2004000234A1 (en) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID |
EP1739078A1 (en) * | 2005-05-30 | 2007-01-03 | Jerini AG | Antagonists of C5a-receptor |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
AR070127A1 (en) * | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
WO2011062955A2 (en) * | 2009-11-18 | 2011-05-26 | University Of Massachusetts | Compounds for modulating tlr2 |
HUE034239T2 (en) | 2010-03-31 | 2018-02-28 | Gilead Pharmasset Llc | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
MX2012010666A (en) * | 2010-03-31 | 2012-10-05 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives. |
WO2012047856A2 (en) | 2010-10-04 | 2012-04-12 | Institute For Hepatitis And Virus Research | Novel inhibitors of secretion of hepatitis b virus antigens |
CA3064103C (en) | 2011-06-30 | 2023-03-07 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of hepatitis b virus |
EP2726459B1 (en) | 2011-07-01 | 2019-09-11 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
ES2649410T3 (en) | 2011-12-21 | 2018-01-11 | Novira Therapeutics Inc. | Antiviral agents for hepatitis B |
CN104822267B (en) | 2012-02-29 | 2018-01-23 | 巴鲁克·S·布伦博格研究所 | The inhibitor and its application method that hepatitis b virus covalence closed cyclic DNA is formed |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
ES2575398T3 (en) | 2012-03-31 | 2016-06-28 | F. Hoffmann-La Roche Ag | Novel 4-Methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
TW201920090A (en) | 2012-08-28 | 2019-06-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
BR112015004161B8 (en) | 2012-08-28 | 2022-11-08 | Janssen Sciences Ireland Uc | FUSIONED BICYCLIC SULFAMOYL DERIVATIVE AND ITS USE IN THE TREATMENT AND PREVENTION OF INFECTION BY HEPATITIS B VIRUS, AS WELL AS PHARMACEUTICAL COMPOSITION AND PRODUCT THAT COMPRISES IT |
SG11201503997VA (en) | 2012-12-06 | 2015-06-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
SG10201803698UA (en) | 2012-12-27 | 2018-06-28 | Univ Drexel | Novel antiviral agents against hbv infection |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
RS57999B1 (en) | 2013-05-17 | 2019-01-31 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
AU2014294997B2 (en) | 2013-07-25 | 2018-03-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR102290189B1 (en) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR20160127714A (en) | 2013-11-14 | 2016-11-04 | 노비라 테라퓨틱스, 인코포레이티드 | Azepane derivatives and methods of treating hepatitis b infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
AU2015212903A1 (en) | 2014-01-30 | 2016-05-19 | F. Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection |
KR20160110419A (en) | 2014-02-06 | 2016-09-21 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
LT3114128T (en) | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
HUE046567T2 (en) | 2014-03-13 | 2020-03-30 | Univ Indiana Res & Tech Corp | Hepatitis b core protein allosteric modulators |
RU2016146365A (en) | 2014-05-13 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | NEW DIHYDROCHINOLYSINE FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION |
BR112016028000B1 (en) | 2014-05-30 | 2022-05-17 | Qilu Pharmaceutical Co., Ltd | Loop derivative of dihydropyrimide as an hbv inhibitor |
BR112017002970B1 (en) | 2014-08-14 | 2023-04-11 | F. Hoffmann-La Roche Ag | NEW PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
JP2018504373A (en) | 2014-12-02 | 2018-02-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | Sulfide alkyl and pyridyl reverse sulfonamide compounds for the treatment of HBV |
WO2016107832A1 (en) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection |
EP3256471B1 (en) | 2015-02-11 | 2018-12-12 | F. Hoffmann-La Roche AG | Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
WO2016128541A1 (en) * | 2015-02-13 | 2016-08-18 | Azienda Ospedaliera Universitaria Senese | Human helicase ddx3 inhibitors as therapeutic agents |
JP6462155B2 (en) | 2015-05-04 | 2019-01-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2017013046A1 (en) | 2015-07-21 | 2017-01-26 | F. Hoffmann-La Roche Ag | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2017016921A1 (en) | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid |
WO2017016960A1 (en) | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues |
CN107820496B (en) | 2015-07-27 | 2020-11-03 | 豪夫迈·罗氏有限公司 | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections |
JP6559324B2 (en) | 2015-07-28 | 2019-08-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Novel 6,7-dihydropyrido [2,1-a] phthalazin-2-ones for the treatment and prevention of hepatitis B virus infection |
TWI721016B (en) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | Hepatitis b core protein modulators |
WO2017064156A1 (en) | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
WO2017102648A1 (en) | 2015-12-15 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue |
MA44075A (en) | 2015-12-17 | 2021-05-19 | Incyte Corp | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN / PROTEIN PD-1 / PD-L1 INTERACTIONS |
WO2017108630A1 (en) | 2015-12-21 | 2017-06-29 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor |
WO2017114812A1 (en) | 2015-12-29 | 2017-07-06 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and an interferon |
BR112018016842A2 (en) | 2016-02-19 | 2018-12-26 | Novartis Ag | tetracyclic pyridone compounds as antivirals |
WO2018026971A1 (en) | 2016-08-03 | 2018-02-08 | Arising International, Llc | Symmetric or semi-symmetric compounds useful as immunomodulators |
ES2941716T3 (en) | 2016-08-29 | 2023-05-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2018045142A1 (en) | 2016-09-02 | 2018-03-08 | Polaris Pharmaceuticals, Inc. | Immune checkpoint inhibitors, compositions and methods thereof |
KR102522060B1 (en) | 2016-11-07 | 2023-04-14 | 아뷰터스 바이오파마 코포레이션 | Substituted pyridinone-containing tricyclic compounds and methods of use thereof |
ES2891528T3 (en) | 2016-12-20 | 2022-01-28 | Bristol Myers Squibb Co | Compounds useful as immunomodulators |
BR112019012993A2 (en) | 2016-12-22 | 2019-12-03 | Incyte Corp | benzo-oxazole derivatives as immunomodulators |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201835049A (en) | 2016-12-22 | 2018-10-01 | 美商英塞特公司 | Heterocyclic compounds as immunomodulators |
EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
US10654815B2 (en) | 2016-12-29 | 2020-05-19 | Shenzhen Chipscreen Biosciences Co., Ltd. | Urea compound and preparation method and application thereof |
CN109678796B (en) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | PD-1/PD-L1 small molecule inhibitor and preparation method and application thereof |
CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
-
2019
- 2019-12-10 TW TW108145199A patent/TWI827760B/en active
- 2019-12-11 AU AU2019397481A patent/AU2019397481B2/en active Active
- 2019-12-11 IL IL310611A patent/IL310611A/en unknown
- 2019-12-11 JP JP2021533746A patent/JP7410950B2/en active Active
- 2019-12-11 CN CN201980091236.1A patent/CN113923988A/en active Pending
- 2019-12-11 IL IL283395A patent/IL283395B1/en unknown
- 2019-12-11 SG SG11202105272YA patent/SG11202105272YA/en unknown
- 2019-12-11 WO PCT/US2019/065756 patent/WO2020123674A1/en unknown
- 2019-12-11 MX MX2021006997A patent/MX2021006997A/en unknown
- 2019-12-11 US US17/298,076 patent/US20230045421A1/en active Pending
- 2019-12-11 BR BR112021011381-9A patent/BR112021011381A2/en unknown
- 2019-12-11 CA CA3122568A patent/CA3122568A1/en active Pending
- 2019-12-11 EP EP19895997.5A patent/EP3893645B1/en active Active
- 2019-12-11 KR KR1020217021614A patent/KR20210102942A/en unknown
-
2021
- 2021-06-10 PH PH12021551369A patent/PH12021551369A1/en unknown
-
2023
- 2023-12-22 JP JP2023216468A patent/JP2024038037A/en active Pending
-
2024
- 2024-01-31 AU AU2024200603A patent/AU2024200603A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230045421A1 (en) | 2023-02-09 |
CA3122568A1 (en) | 2020-06-18 |
JP2022513845A (en) | 2022-02-09 |
AU2019397481A1 (en) | 2021-06-10 |
BR112021011381A2 (en) | 2021-08-31 |
EP3893645A4 (en) | 2022-08-03 |
JP2024038037A (en) | 2024-03-19 |
CN113923988A (en) | 2022-01-11 |
JP7410950B2 (en) | 2024-01-10 |
TW202035359A (en) | 2020-10-01 |
PH12021551369A1 (en) | 2021-11-29 |
AU2024200603A1 (en) | 2024-02-22 |
TWI827760B (en) | 2024-01-01 |
IL283395A (en) | 2021-07-29 |
KR20210102942A (en) | 2021-08-20 |
WO2020123674A1 (en) | 2020-06-18 |
AU2019397481B2 (en) | 2023-12-14 |
EP3893645B1 (en) | 2024-04-17 |
IL283395B1 (en) | 2024-03-01 |
EP3893645A1 (en) | 2021-10-20 |
IL310611A (en) | 2024-04-01 |
MX2021006997A (en) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3601216A4 (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
ZA201906131B (en) | Herbicidal mixture, composition and method | |
IL283395A (en) | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same | |
ZA201907833B (en) | Heteroarylphenylaminoquinolines and analogues | |
GB2576614B (en) | Compositions, uses and methods | |
GB201804163D0 (en) | Uses, compositions and methods | |
GB201803724D0 (en) | Methods | |
SG11202008132UA (en) | Composition, method and use | |
GB2564511B (en) | Composition, method and use | |
GB201805016D0 (en) | Composition, method and use | |
GB201805095D0 (en) | Compostion, method and use | |
GB201802486D0 (en) | Methods | |
GB2603879B (en) | Card-handling devices and related methods, assemblies, and components | |
GB201805466D0 (en) | Methods | |
GB2591917B (en) | Card-handling devices and related methods, assemblies, and components | |
EP3906225C0 (en) | Pantothenamide analogues | |
PL3750893T3 (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
GB2575417B (en) | Carabiner | |
GB201814451D0 (en) | Methods | |
GB201715724D0 (en) | Devices,and methods and uses relating thereto | |
GB201812776D0 (en) | New methods and uses | |
GB201902266D0 (en) | New methods and uses | |
GB201810747D0 (en) | Methods | |
GB201808714D0 (en) | Methods | |
AU2017904353A0 (en) | Substituted ureas, their analogues and uses thereof |